文献速递妇科产科

早期宫颈癌开腹与腹腔镜辅助阴式根治性子宫切除术长期生存比较

Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.
PubMed 文献 · Gynecol Oncol · 2020-10-09

韩国3家机构2008–2017年812例IA2–IB2期宫颈癌患者中,258例接受TARH、252例接受LARVH。两组5年PFS(84.4% vs 86.6%)和OS(85.8% vs 88.0%)相近,LARVH对TARH的PFS与OS非劣效性均成立。

要点

  • 早期宫颈癌中LARVH的5年PFS和OS非劣效于TARH。
  • 肿瘤>2 cm亚组两术式5年PFS与OS差异无统计学意义。
  • LARVH可能具有肿瘤学安全性,但需结合患者选择。

核心结论

  • 在IA2–IB2期宫颈癌中,LARVH对TARH的PFS和OS均显示非劣效性。
  • LARVH可能具有肿瘤学安全性。

研究设计与样本

  • 韩国3家机构2008–2017年的多中心回顾性分析。
  • 共评估812例接受根治性子宫切除术的患者,其中258例TARH、252例LARVH。
  • 采用Kaplan-Meier法分析PFS和OS,log-rank检验比较,非劣效界值为-7.2%。

主要发现

  • TARH与LARVH组5年PFS分别为84.4%与86.6%(p=0.467)。
  • TARH与LARVH组5年OS分别为85.8%与88.0%(p=0.919)。
  • LARVH对TARH的5年PFS差异为2.2%(95%CI -2.9–7.3,p=0.001),OS差异为2.2%(95%CI -2.7–7.1,p=0.001),非劣效性成立。
  • 肿瘤>2 cm亚组中,两组5年PFS为77.6% vs 79.0%(p=0.682),OS为79.2% vs 81.5%(p=0.784)。
  • 该亚组LARVH对TARH的5年PFS差异为1.4%(95%CI -7.0–9.8,p=0.046),OS差异为2.3%(95%CI -5.8–10.4,p=0.027),非劣效性亦成立。

关键数值与推荐

  • 非劣效界值预设为-7.2%,若95%CI下限超过该界值则判定非劣效。
  • 全组5年PFS差异95%CI下限-2.9%高于-7.2%,OS差异95%CI下限-2.7%高于-7.2%。
  • 肿瘤>2 cm亚组5年PFS差异95%CI下限-7.0%高于-7.2%,OS差异95%CI下限-5.8%高于-7.2%。

临床怎么用

  • 对于IA2–IB2期宫颈癌,LARVH可作为TARH的潜在替代术式。
  • 肿瘤>2 cm患者选择LARVH时,现有数据支持其非劣效生存。
  • 需结合术者经验与患者具体情况个体化决策。

局限性

  • 为回顾性分析,可能存在选择偏倚。
  • 原文未报告随访时长、失访率及并发症等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare survival outcomes of total abdominal radical hysterectomy (TARH) versus laparoscopy-assisted radical vaginal hysterectomy (LARVH) in stage IA2-IB2 cervical cancer. METHODS: 812 patients who underwent RH between 2008 and 2017 were evaluated in 3 institutions. Progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier method and compared by log-rank test. The clinical noninferiority of the LARVH to TARH was assessed with a margin of -7.2%. Noninferiority was demonstrated if the low limit of 95% confidence interval (CI) exceeded its predefined margin. RESULTS: 258 patients were treated with TARH and 252 patients with LARVH. TARH and LARVH group had similar 5-year PFS (84.4% vs 86.6%, p = 0.467) and OS rates (85.8% vs 88.0%, p = 0.919). Noninferiority of LARVH to TARH were confirmed with 5-year PFS and OS difference rates of 2.2% (95% CI -2.9-7.3, p = 0.001) and 2.2% (95% CI -2.7-7.1, p = 0.001), respectively. In subgroup of patients with tumors size >2 cm, 5-year PFS (77.6% vs 79.0%, p = 0.682) and OS rates (79.2% vs 81.5%, p = 0.784) did not differ statistically between the two groups. Noninferiority of LARVH to TARH were also confirmed with 5-year PFS and OS difference rates of 1.4% (95% CI -7.0-9.8, p = 0.046) and 2.3% (95% CI -5.8-10.4, p = 0.027), respectively. CONCLUSION: LARVH showed significant noninferiority for PFS and OS versus TARH in early cervical cancer, suggesting the potential oncologic safety of LARVH.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kwon BS, Roh HJ, Lee S, et al. Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis. Gynecol Oncol. 2020. PMID: 33041070. doi:10.1016/j.ygyno.2020.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。